tbuckley/cabot-search huggingface dataset:
P9 The utility of p16 fish in differentiating malignant mesothelioma and benign mesothelial proliferations
Authors: A Chaturvedi, J Holme, R Shah, P Taylor, M Evison
Journal: Thorax (2016)

<h3>Introduction</h3> One of the commonest genetic abnormalities in malignant mesothelioma is deletion of the 9p21 locus which harbours the p16/CDKN2A gene. Homozygous deletion of p16/CDKN2A can be identified with Fluorescence in situ hybridization (FISH) and may be a useful diagnostic tool where there is difficulty separating malignant from benign mesothelial cell proliferations, e.g. where a lack of invasion into adipose tissue prevents a confident diagnosis of mesothelioma. <h3>Methods</h3> The University Hospital of South Manchester is a regional mesothelioma centre in the North West of England. p16 FISH has been in clinical use since 2013 for cases of abnormal mesothelial cell proliferation without conclusive evidence of malignancy. This retrospective study analysed the diagnostic performance of p16 FISH using clinical follow-up and post-mortem studies to clarify final diagnoses. <h3>Results</h3> 75 pathological samples underwent p16 FISH analysis 2013–2015; 16 cytology samples (14 pleural fluid, 2 ascitic fluid), 36 VATS pleural biopsies, 16 local anaesthetic thoracoscopy pleural biopsies and 7 percutaneous pleural biopsies. There was one failed test. A final diagnosis based on subsequent definitive pathological sampling, definitive radiological surveillance or post-mortem findings were available for 99% of patient (74/75). 71 patients were ultimately proven to have mesothelioma (39 epithelioid, 13 sarcomatoid, 7 biphasic and 12 NOS), 2 patients were diagnosed benign pleural disease and 1 with metastatic lung cancer. The diagnostic performance of p16 FISH was as follows: sensitivity 69%, specificity 100%, positive predictive value 100%, negative predictive value 8%, and diagnostic accuracy 69%. All positive p16 FISH results were in cases of mesothelioma. The sensitivity of p16 according to specimen type was as follows: fluid cytology 88%, VATS 59%, medical thoracoscopy 57% and percutaneous biopsy 50%. The sensitivity as per histological subtype for p16 FISH was 66% in epithelioid mesothelioma and 73% in sarcomatoid mesothelioma. <h3>Discussion</h3> p16 FISH is a useful diagnostic tool to confirm cases of suspected malignant mesothelioma. A positive result is consistent with mesothelioma but a negative result does not exclude it. This data shows promising diagnostic yield in fluid cytology which may be especially relevant in those patients unsuitable for invasive biopsies due to technical or clinical reasons.
MA04.02 Neratinib ± Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
Authors: Leena Gandhi, Benjamin Besse, Julien Mazieres, Saiama Waqar, Alexis Cortot, Fabrice Barlesi, Elisabeth Quoix, Gregory Otterson, David Ettinger, Leora Horn, Denis Moro-Sibilot, Mark Socinski, Kathryn Gold, Jhanelle Gray, Ana Oton, Rebecca Suk Heist, Daniel Costa, Leanne Mcculloch, Judith Bebchuk, Richard Bryce, Mark Kris
Journal: Journal of Thoracic Oncology (2017)
Early Deficiency of Endogenous Proteins Inhibiting LPS-Induced TNF-α Production Correlates with Acute Graft vs Host Disease (aGVHD) after Myeloablative Stem Cell Transplantation (SCT).
Authors: Ofer Levy, Eugenie E. Suter, Leslie A. Kalish, Patrick Scannon, Jerrold P. Weiss, Athmane Teghanemt, Janice D. Russell, Leighanne C. Gallington, Hoi M. Leung, Robert J. Soiffer, Suganya Viriyakosol, Gregory Priebe, Michael R. Wessels, Eva C. Guinan
Journal: Blood (2007)
Correlation between change of serum HER2/neu before and after neoadjuvant chemotherapy and clinical outcomes in advanced breast cancers.
Authors: J. S. Lee, C. Jeon, M. Park, J. Y. Sin
Journal: Journal of Clinical Oncology (2011)

e21067 Background: We searched for correlation between the response of advanced breast cancers in neoadjuvant chemotherapy and the change of serum HER2/neu, and short term disease free survival. Methods: 22 localized advanced breast cancer patients were treated by neoadjuvant chemotherapy (adriamycin: 17, trastuzumab: 5). We concerned HER2/neu positive breast cancer when IHC3+ or FISH amplified. Serum HER2/neu levels were measured by chemiluminescence immunoassay (ADVIA centaurTM system) before neoadjuvant chemotherapy and before operation. The cutoff value was 10.2 mg/ml according to previous study. We considered clinical outcomes as short term disease free survival and disease free interval for investigating of the role of serum HER2/neu in a prediction of clinical outcomes. Results: Mean of serum HER2/neu before chemotherapy was 15.8± 1.6ng/ml, and that after chemotherapy was 10.6 ± 0.38ng/ml. Partial response (PR) was 17 patients and complete response (CR) was 5 patients. Mean of change in serum HER2/neu was 5.1± 2.1ng/ml, and change of serum HER2/neu in CR group was higher than PR group (13.26 ± 14.1ng/ml; 2.74±3.2ng/ml,p=0.008). Change of serum HER2/neu in trastuzumab group was higher than that in adriamycin group (12.8±14.5ng/ml; 2.8±3.2ng/ml, p=0.012). In adriamycin group, CR was not correlated with change of serum HER-2/neu (PR: 3.03±3.3NG/ML; CR: 1.65±1.62ng/ml, p=0.58). In trastuzumab group, it also was not correlated (PR: 0.6 ±1.13ng/ml; CR: 21.0 ±13.2ng/ml, p=0.083). CR was correlated with change of serum HER2/neu, initial serum HER2/neu, and treatment group (T>A, p=0.024). Mean follow up duration was 41months, the change of serum HER2/neu before and after chemotherapy was not correlated with disease recurrence (NED: 8.6± 11.4ng/ml, REC: 2.1± 0.65ng/ml, p=0.082). The change of serum HER2/neu was not correlated with disease free interval (p=0.07). Conclusions: The change in serum HER2/neu was associated with pathologic response with neoadjuvant chemotherapy, but not specific in the chemoregimen. The bigger change of serum HER2/neu, the better prognosis was estimated, even a limited study, but it needs further studies.
P2.03a-061 Randomized Phase II Trial Comparing Intercalation of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy
Authors: Shinkyo Yoon, Dae Ho Lee, Deokhoon Kim, Chang-Min Choi, Sang-We Kim
Journal: Journal of Thoracic Oncology (2017)
S102 Vitamin d supplementation to prevent acute respiratory infections: systematic review and meta-analysis of individual participant data
Authors: AR Martineau, DA Jolliffe, RL Hooper, L Greenberg, JF Aloia, P Bergman, G Dubnov-Raz, S Esposito, D Ganmaa, EC Goodall, C Grant, W Janssens, I Laaksi, S Manaseki-Holland, D Murdoch, RE Neale, JR Rees, S Simpson, I Stelmach, G Trilok Kumar, M Urashima, CA Camargo
Journal: Thorax (2016)

<h3>Introduction and objectives</h3> Randomised controlled trials of vitamin D to prevent acute respiratory infection have yielded mixed results. We conducted an individual patient data (IPD) meta-analysis to identify factors that may explain this heterogeneity. <h3>Methods</h3> We performed an IPD meta-analysis of 25 trials of vitamin D supplementation with incidence of acute respiratory infection as a pre-specified outcome (total 11,321 participants, aged 0 to 95 years). We used one-step logistic regression with random effects adjusting for age, sex, study duration and clustering by study. Pre-specified sub-group analyses were done to determine whether effects of vitamin D on risk of acute respiratory infection varied according to baseline 25-hydroxyvitamin D (25[OH]D) concentration or dosing regimen. <h3>Results</h3> IPD were obtained for 10,933/11,321 (96.6%) participants. Vitamin D supplementation reduced risk of acute respiratory infection among all participants (adjusted Odds Ratio [aOR] 0.88, 95% CI: 0.81 to 0.96, P = 0.003; P for heterogeneity &lt; 0.001). Sub-group analysis revealed a strong protective effect among individuals with baseline 25(OH) D &lt; 25 nmol/L (aOR 0.62, 95% CI: 0.45 to 0.83, P = 0.002), not seen among those with higher levels (aOR 0.91, 95% CI: 0.78 to 1.05; Pinteraction = 0.01). A protective effect was also seen in individuals receiving daily or weekly vitamin D without additional bolus doses (aOR 0.81, 95% CI: 0.72 to 0.91, P &lt; 0.001), but not in those receiving one or more bolus doses (aOR 0.97, 95% CI: 0.86 to 1.10, Pinteraction = 0.05). Vitamin D did not influence the proportion of participants experiencing at least one serious adverse event (aOR 0.98, 95% CI: 0.80 to 1.20, P = 0.83). The body of evidence contributing to these analyses was assessed as being of high quality. <h3>Conclusions</h3> Vitamin D supplementation was safe, and it protected against acute respiratory infection overall. Very deficient individuals and those not receiving bolus doses experienced the most benefit.
In Vitro Testing of Suppresion of T Regulatory Cells ( Treg) by Lenalidomide Is Correlated to Treatment Response of Lenalidomide in Patients with Primary Myelofibrosis ( PMF).
Authors: Jen-Chin Wang, Chi Chen, Chentyl Rathnasabapathy, Muhammad I. Kafeel, Amrit Singh, Yiwu Sun
Journal: Blood (2009)
The Novel, Orally Available Multi-Kinase Inhibitor BAY 73-4506 Targets Myeloma Cells and Their Bone Marrow Microenvironment.
Authors: Marc S. Raab, Iris Breitkreutz, Podar Klaus, Jing Zhang, Simona Blotta, Olaf Christensen, Teru Hideshima, Dharminder Chauhan, Scott Wilhelm, Kenneth C. Anderson
Journal: Blood (2007)
Distinct Expression Patterns of Human microRNAs in Myeloid Differentiation and Acute Myeloid Leukemia.
Authors: Fabienne Isken, Björn Steffen, Birgit Markus, Claudia Hömme, David Kosel, Thomas Illmer, Sylvia Merk, Martin Dugas, Wolfgang E. Berdel, Hubert Serve, Carsten Müller-Tidow
Journal: Blood (2006)
Association Between Antipsychotic Agents and Risk of Acute Respiratory Failure in Patients With Chronic Obstructive Pulmonary Disease
Authors: Meng-Ting Wang, Chen-Liang Tsai, Chen Wei Lin, Chin-Bin Yeh, Yun-Han Wang, Hui-Lan Lin
Journal: JAMA Psychiatry (2017)

Acute respiratory failure (ARF) is a life-threatening event that has been linked in case reports to antipsychotic use, but this association lacks population-based evidence. Particular attention should be focused on patients with chronic obstructive pulmonary disease (COPD) regarding this drug safety concern because these patients are prone to ARF and are commonly treated with antipsychotics.To determine whether the use of antipsychotics is associated with an increased risk of ARF in patients with COPD.A population-based case-crossover study analyzing the Taiwan National Health Insurance Research Database was conducted of all patients with COPD, who were newly diagnosed with ARF in hospital or emergency care settings necessitating intubation or mechanical ventilation from January 1, 2000, to December 31, 2011. Patients with prior ARF, lung cancer, and cardiogenic, traumatic, or septic ARF were excluded to analyze idiopathic ARF. The pilot study was conducted from November 1 to December 31, 2013, and full data analysis was performed from October 15, 2015, to November 8, 2016.The use of antipsychotics was self-compared during days 1 to 14 (the risk period according to previous case reports) and days 75 to 88 (control period) preceding the ARF event or index date. The antipsychotic class, route of administration, and dose were also examined.Risk of ARF.There were 5032 patients with ARF (mean [SD] age, 74.4 [9.9] years; 3533 males [70.2%]) among the 61 620 patients with COPD. Five hundred ninety patients with ARF (11.7%) filled at least 1 antipsychotic prescription during the case period compared with 443 (8.8%) during the control period, corresponding to a 1.66-fold (95% CI, 1.34-2.05; P < .001) adjusted increased risk of ARF regardless of antipsychotic class and administration route. A dose-dependent risk of ARF associated with antipsychotics was identified (test for trend, adjusted odds ratio, 1.35; 95% CI, 1.19-1.52; P < .001), which increased from a 1.52-fold risk for a low daily dose (95% CI, 1.20-1.92; P < .001) to a 3.74-fold risk for a high dose (95% CI, 1.68-8.36; P = .001). The increased risk persisted under a case-time-control analysis (adjusted odds ratio, 1.62; 95% CI, 1.16-2.27; P = .005) and nested case-control study (adjusted odds ratio, 2.16; 95% CI, 1.91-2.15; P < .001).Antipsychotic use is associated with an acute and dose-dependent increased risk of ARF in patients with COPD. Clinicians should exercise caution when prescribing antipsychotics to patients with COPD and avoid high doses if possible.
P3.02b-042 Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib
Authors: Aaron Lisberg, John Horton, Jonathan W. Goldman, Brian Wolf, D. Andrew Tucker, James Carroll, Phillip Abarca, Jennifer Strunck, Maria Velez, Sina Famenini, Jamie Hunt, Krikor Bornazyan, Timothy Ellis-Caleo, Xinkai Zhou, Tristan Grogan, David Elashoff, Patricia Young, Richard Pietras, Steven Dubinett
Journal: Journal of Thoracic Oncology (2017)
CHIR-12.12, an Antagonist Anti-CD40 Antibody, Exhibits Greater ADCC Than Rituximab Against a Variety of Malignant B Cells: Evaluation of FcγRIIIa Polymorphism and ADCC Response.
Authors: Mohammad Luqman, Xia Tong, Xiaohong Niu, Pablo Garcia, Michel Faure, Asha Yabannavar, Bahija Jallal
Journal: Blood (2005)
P3.02b-087 Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PEM with Erlotinib and Bev for Non-SQ NSCLC Harboring EGFR Mutations
Authors: Motohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, Sawa Takeoka, Yujiro Naito, Naoki Omachi, Yohei Kimura, Naoko Morishita, Hidekazu Suzuki, Norio Okamoto, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi, Tomonori Hirashima
Journal: Journal of Thoracic Oncology (2017)
Care of the Injured Patient
Authors: Joseph V. Sakran
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Association of GP88 (progranulin) tumor expression with decreased disease-free and overall survivals in patients with breast cancer with estrogen receptor-positive invasive ductal carcinoma.
Authors: G. Serrero, D. M. Hawkins, B. Yue, O. B. Ioffe, P. Bejarano, J. T. Phillips, J. F. Head, R. L. Elliott, A. K. Godwin, J. Weaver, W. Kim, S. Kamimura
Journal: Journal of Clinical Oncology (2011)

604 Background: GP88 (progranulin) is an autocrine growth factor produced by breast cancer cells in a positive correlation with tumorigenicity. It was shown that estrogen receptor positive (ER+) breast cancer. cells that are naturally resistant to anti-estrogen therapies overexpressed GP88. Previous pathological studies with 203 paraffin embedded breast biopsies have shown that GP88 is expressed in invasive ductal carcinoma (IDC), but not in normal mammmary tissue, benign lesions and lobular carcinoma. Based on these data, the present study examined whether GP88 was a prognostic factor associated with poor clinical outcomes for patients with ER+ IDC. Methods: A training trial followed by an independent retrospective multi-site study totaling 565 ER+ IDC cases were carried out. GP88 expression was examined by immunohistochemistry in tissue sections from paraffin embedded blocks using an anti-human GP88 monoclonal antibody. Scoring of stained slides was performed by board certified pathologists. Statistical analysis of the GP88 expression results was based on evaluating the GP88 test performance for its association with disease-free survival (DFS) and overall survival (OS) using Kaplan Meier curves and the Cox Proportional Hazard models for quantification of risk. Results: The training trial established that a GP88 score of 3+ was associated with decreased DFS (p=0.0004) and OS (p=0.0036). The independent validation study verified the GP88 cut-off value and showed that GP88 score of 3+ was associated with a 5.9-fold higher hazard of disease recurrence and a 2.5-fold higher mortality hazard, respectively, when compared to patients with tumor GP88<3+. GP88 was an independent risk predictor even taking into account lymph node status, tumor size, tumor grade, and disease stage. Conclusions: The survival factor GP88 is a prognostic factor for patients with ER+IDC and is associated with poor survival outcomes. The data presented here would support further investigation to examine whether high tumor GP88 expression is associated with decreased response to anti-estrogen therapies in patients with ER+ IDC.
P3.03-024 Malignant Pleural Mesothelioma: Gene Expression Profiling of the Main Histological Subtypes
Authors: Greta Alì, Rossella Bruno, Riccardo Giannini, Agnese Proietti, Antonio Chella, Alfredo Mussi, Gabriella Fontanini
Journal: Journal of Thoracic Oncology (2017)
Cancer statistics, 2017
Authors: Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal
Journal: CA A Cancer Journal for Clinicians (2017)

Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the Surveillance, Epidemiology, and End Results Program; the National Program of Cancer Registries; and the North American Association of Central Cancer Registries. Mortality data were collected by the National Center for Health Statistics. In 2017, 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the United States. For all sites combined, the cancer incidence rate is 20% higher in men than in women, while the cancer death rate is 40% higher. However, sex disparities vary by cancer type. For example, thyroid cancer incidence rates are 3-fold higher in women than in men (21 vs 7 per 100,000 population), despite equivalent death rates (0.5 per 100,000 population), largely reflecting sex differences in the "epidemic of diagnosis." Over the past decade of available data, the overall cancer incidence rate (2004-2013) was stable in women and declined by approximately 2% annually in men, while the cancer death rate (2005-2014) declined by about 1.5% annually in both men and women. From 1991 to 2014, the overall cancer death rate dropped 25%, translating to approximately 2,143,200 fewer cancer deaths than would have been expected if death rates had remained at their peak. Although the cancer death rate was 15% higher in blacks than in whites in 2014, increasing access to care as a result of the Patient Protection and Affordable Care Act may expedite the narrowing racial gap; from 2010 to 2015, the proportion of blacks who were uninsured halved, from 21% to 11%, as it did for Hispanics (31% to 16%). Gains in coverage for traditionally underserved Americans will facilitate the broader application of existing cancer control knowledge across every segment of the population. CA Cancer J Clin 2017;67:7-30. © 2017 American Cancer Society.
Inhibiting PIM-1 Is Effective in Vitro and in Vivo against ALL: A Novel Mechanistic and Potentially Clinically Relevant Druggable Target.
Authors: Valerie I. Brown, Cecilia Sheen, Jessica Hulitt, Theresa Ryan, Laura DiNardo, David Barrett, David T. Teachey, David J. Bearss, Gregory I. Berk, Stephan A. Grupp
Journal: Blood (2008)
Updated Recommendations for Cost-effectiveness Studies
Authors: Stephen Jan, Virginia Wiseman
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
S132 A randomised controlled study of lung cancer screening in scotland using the detection of autoantibodies to tumour antigens (earlycdt-lung test)
Authors: A Dorward, F Frances Mair, F Sullivan, K Vedhara, D Kendrick, S Treweek, C McCowan, A McConnachie, M Sproule, A Briggs, L Ritchie, R Milroy, T Taylor, R Littleford, D Brewster, S Schembri
Journal: Thorax (2016)

<h3>Background</h3> EarlyCDT®-Lung Test detects autoantibodies to abnormal cell surface proteins from the early stages of lung cancer with a specificity of 93%. This may allow earlier tumour detection thus altering prognosis. The primary research question is: Does using the EarlyCDT®-Lung Test to identify those at high risk of lung cancer, followed by xray and CT scanning in the test positive group, reduce the incidence of patients with late-stage lung cancer (III and IV) or unclassified presentation (U) at diagnosis, compared to standard practice? Recruitment was completed in June 2016 with 12,018 subjects randomised. <h3>Methods</h3> A RCT in Scotland recruiting from the most socially disadvantaged quintiles. Adults aged 50 to 75 (ECOG 0–2) who were at high risk for lung cancer (&gt;20 pack years or relevant family history) were eligible. The intervention was the EarlyCDT®-Lung Test, followed by chest xray and CT in those with a positive result. The comparator is standard clinical practice in the UK. The primary outcome is the difference, after 24 months, between the rates of patients with stage III, IV or unclassified lung cancer at diagnosis in test v no-test group. Secondary outcomes include: all-cause mortality; cancer specific mortality; a range of morbidity outcomes; cost-effectiveness and measures examining the psychological and behavioural consequences of screening. Participants with a positive test result had an initial chest xray which was used to determine the urgency and the need for contrast in the initial screening CT. Those in whom the initial CT scan did not lead to a lung cancer diagnosis were offered biannual chest CTs for 24 months. Participants who are found to have lung cancer will be followed-up to assess both time to diagnosis and stage of disease at diagnosis. <h3>Results</h3> 575/6120 (9.8%) of the test group had a positive test with 207 found to have lung nodules &gt;8 mm, 16 cancers have been detected so far, 12 of which are at early stage. Eleven have abnormalities undergoing current investigation. At this stage of the trial we have no outcome data for the comparison group. <h3>Conclusion</h3> The study will determine EarlyCDT-Lung test’s clinical and cost effectiveness.